The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity

BB Hasinoff, PE Schroeder, D Patel - Molecular pharmacology, 2003 - ASPET
The clinically approved cardioprotective agent dexrazoxane (ICRF-187) and two of its
hydrolyzed metabolites (a one-ring open form of dexrazoxane and ADR-925) were examined for …

Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development

SA Peters, PE Schroeder, N Giri, H Dolgos - Drug Metabolism and …, 2012 - ASPET
Simcyp, a population-based simulator, is widely used for evaluating drug-drug interaction (DDI)
risks in healthy and disease populations. We compare the prediction performance of …

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

PE Schroeder, BB Hasinoff - Drug metabolism and disposition, 2005 - ASPET
Dexrazoxane (ICRF-187) is clinically used as a doxorubicin cardioprotective agent and may
act by preventing iron-based oxygen free radical damage through the iron-chelating ability …

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

PE Schroeder, PB Jensen, M Sehested… - Cancer chemotherapy …, 2003 - Springer
Purpose The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187)
to its one-ring open hydrolysis products and its two-rings opened metal-chelating product …

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

PE Schroeder, BB Hasinoff - Cancer chemotherapy and pharmacology, 2002 - Springer
Purpose. Dexrazoxane is clinically used as a doxorubicin-cardioprotective agent and may
act by preventing iron-based oxygen free-radical damage through the iron-chelating ability of …

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)

PE Schroeder, JN Davidson, BB Hasinoff - Drug metabolism and disposition, 2002 - ASPET
The enzyme kinetics of the hydrolysis of the one-ring open metabolites of the antioxidant
cardioprotective agent dexrazoxane [ICRF-187; (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane] to …

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

PE Schroeder, D Patel, BB Hasinoff - Drug metabolism and disposition, 2008 - ASPET
Dexrazoxane (ICRF-187) is clinically used as a doxorubicin cardioprotective agent and to
prevent anthracycline extravasation injury. It may act by preventing iron-based oxygen free …

Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood

PE Schroeder, GQ Wang, FJ Burczynski… - Drug metabolism and …, 2005 - ASPET
The metabolism of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and one
of its one-ring open metabolites to its active metal ion binding form N,N′-[(1S)-1-methyl-1,2-…

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

PE Schroeder, KF Hofland, PB Jensen… - Cancer chemotherapy …, 2004 - Springer
Purpose The pharmacokinetics of etoposide were studied in cancer patients with brain
metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were …

Interaction among spring phytoplankton succession, water discharge patterns, and hydrogen peroxide dynamics in the Caloosahatchee River in southwest Florida

…, JH Steele, TL Hancock, EK Dahedl, ER Schroeder… - Harmful algae, 2023 - Elsevier
Phytoplankton communities are major primary producers in the aquatic realm and are
responsible for shaping aquatic ecosystems. The dynamics of algal blooms could be determined …